TuHURA Biosciences, Inc.

NASDAQ: HURA · Healthcare · Biotechnology

PublicHQ Tampa, CIK 0001498382Reports USD

#1143 of 1,394 Healthcare companies by revenue

EA Score

35D

FH 43DQ 19GM —SS 54

v0.1 · 55/100 weight · provisional

↑ Altman-Z, balance-sheet leverage · ↓ Piotroski F, disclosure history

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$30.1M

Employees

Market cap

$155.4M

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$0$02025

Net income-$30.1M-$30.1M2025

Operating income-$57.6k-$57.6k2012

Total assets$27.4M$27.4M2025

Liabilities$6.4M$6.4M2025

Equity$20.9M$20.9M2025

Revenue trend

FY2012 – FY2025 · USD

FY12

FY24

FY25

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

TuHURA Biosciences, Inc. booked $0 in FY2025 revenue — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.

Peers · Healthcare

Vaxart, Inc.73B American Well Corporation59C Protara Therapeutics, Inc.42D Insight Molecular Diagnostics Inc.37D

Key facts

CEOJames A. Bianco

SectorHealthcare

IndustryBiotechnology

HeadquartersTampa, null

ExchangeNASDAQ: HURA

Employees19

IPO date2013-02-22

Latest filings

DEF 14A2026-07-09 8-K2026-07-07 8-K2026-06-17 8-K2026-05-29 10-Q2026-05-15 8-K2026-05-15 8-K2026-04-22 8-K2026-04-08

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.